Relationship between total mortality and cholesterol reduction as found by meta-regression analysis of randomized cholesterol-lowering trials

Controlled Clinical Trials

Volumn 17, Issue 1, 1996, Pages 13-22

  Holme, Ingar ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

cholesterol; meta analysis; randomized trials; regression; total mortality; treatment

Indexed keywords

CLOFIBRATE; DEXTROTHYROXINE; NICOTINIC ACID;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RISK FACTOR;

EID: 0029987834     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/0197-2456(95)00083-6     Document Type: Article

References (51)

1. Yusuf S, Furberg CD: Single factor trials: control through life-style changes. In Olsson AG, ed. Atherosclerosis: Biology and Clinical Science. Edinburgh, Churchill Livingstone, 1987, pp. 389-392
2. Yusuf S, Cutler J: Single factor trials: drug studies. In Olsson AG, ed. Atherosclerosis: Biology and Clinical Science. Edinburgh, Churchill Livingstone, 1987, pp. 393-398
3. Muldoon MF, Manuck SB, Matthews KA: Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. Br Med J 305:1226-1227, 1992
4. Silberberg JS, Henry DA: The benefits of reducing cholesterol levels: the need to distinguish primary from secondary prevention. Med J Aust 155:665-674, 1991
5. Ravnskov U: Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome. Br Med J 305:9-15, 1992
6. Holme I: Relation of coronary heart disease incidence and total mortality to plasma cholesterol reduction in randomised trials: use of meta-analysis. Br Heart J 69(Suppl): S42-47, 1993
7. Davey-Smith G, Song F, Sheldon TA: Cholesterol lowering and mortality; the importance of considering initial level of risk. Br Med J 306:1367-1373, 1993
8. Gould LA, Rossouw JE, Santanello NC, Heyse JE, Furberg CD: Cholesterol reduction yields clinical benefit: a new look at old data. Circulation 91:2274-2282, 1995
9. Rose GA, Thomson WB, Williams RT: Corn oil in treatment of ischaemic heart disease. Br Med J 1:1531-1533, 1965
10. Research Committee: Low-fat diet in myocardial infarction: a controlled trial. Lancet 2:501-504, 1965
11. Marmorston J, Moore FJ, Hopkins CE, Kuzma OT, Weiner J: Clinical studies of long-term estrogen therapy in men with myocardial infarction. Proc Soc Exp Biol Med 110: 400-408, 1962
12. Stamler J, Pick R, Katz LN, Pick A, Kaplan BM, Berkson DM, et al: Effectiveness of estrogens for therapy of myocardial infarction in middle-age men. JAMA 183:632-638, 1963
13. Harrold BP, Marmion VJ, Gough KR: A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy. Diabetes 18:285-291, 1969
14. Stamler J, Stamler R, Brown V, Gotto AM, Greenland P, Grundy S, Hegsted M, Leupker RV, Neaton JD, Steinberg D, Stone N, VanHorn L, Wissler RW: Serum cholesterol. Doing the right thing (Editorial). Circulation 88:1954-1960, 1993
15. Frantz ID, Dawson EA, Ashman PL, Gatewood LC, Bartsch GE, Kuba K, et al: A test of effect of lipid lowering by diet on cardiovascular risk. The Minnesota coronary survey. Atherosclerosis 9:129-135, 1989
16. Burr ML, Gilbert JF, Holliday RM, Sweetnam PM, Elwood PC, Deadmen NM: Effects of changes in fat, fish and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 2:752-761, 1989
17. Leren P: The effects of plasma cholesterol lowering diet in male survivors of myocardial infarction: a controlled clinical trial. Acta Med Scand (Suppl 166):1-92, 1966
18. Research Committee: Controlled trial of soya-bean oil in myocardial infarction. Lancet 2:693-670, 1968
19. Singh RB, Rastogi SS, Verma R, Laxmi B, Reema BL, Singh R, et al: Randomised controlled trial of cardioprotective diet in patients with recent myocardial infarction. Br Med J 304:1015-1019, 1992
20. Woodhill JM, Palmer AJ, Leelarthaepin B, McGilchrist C, Blacket RB: Low fat, low cholesterol diet in secondary prevention of coronary heart disease. Adv Exp Med Biol 109:317-330, 1978
21. Wilhelmsen L, Berglund G, Elmfeldt D, Tibblin G, Wedel H, Pennert K, Vedin A, Wilhelmsen C, Werkoe L. The multi-factor primary prevention trial in Goteborg, Sweden. Eur Heart J 7:279-288, 1986
22. Miettinen TA, Huttunen JK, Kaukkarinen V, et al: Multi factorial prevention of cardiovascular diseases in middle-aged men: risk factor changes, incidence, and mortality. JAMA 254:2097-2102, 1985
23. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA 248:1465-1477, 1982
24. Hjermann I, Holme I, Byre KV, Leren P: Effect of diet and smoking intervention on the incidence of coronary heart disease. Lancet 2:1303-1310, 1981
25. World Health Organization European Collaborative Group. European collaborative trial of multifactorial prevention of coronary heart disease. Final report on the 6 year results. Lancet 1:869-872, 1986
26. Dorr AE, Gundersen K, Schneider JC, Spencer TW, Marun WB: Cholestipol hydrochloride in hypercholesterolemic patients-effects on serum cholesterol and mortality. J Chron Dis 31:5-14, 1978
27. Frick MH, Elo O, Haapa K, Heinonen AP, Heinsalmi P, Helo P, et al: Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 317:1237-1245, 1987
28. Lipid Research Clinics Program: The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 251: 351-364, 1984
29. Committee of Principal Investigation; A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 40:1069-1118, 1978
30. Heady JA, Morris JN, Oliver MF: WHO clofibrate/cholesterol trial clarifications. Lancet 2:1405-1406, 1992
31. Acheson J, Hutchinson EC: Controlled trial of clofibrate in cerebral vascular disease. Atherosclerosis 15:177-183, 1972
32. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, et al: Fifteen year mortality in coronary drug project patients: long-term benefits with niacine. J Am Coll Cardiol 8:1245-1250, 1986
33. Coronary Drug Project Research Group: Clofibrate and niacine in coronary heart disease. JAMA 231:360-380, 1985
34. Bradford RH, Shear CL, Chremos AN, Dujorne C, Franklin FA, Hesney M, et al: Expanded clinical evaluation of lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 151:43-49, 1991
35. Frick MH, Heinonen OP, Huttunen JK, Koskinen P, Manttari M, Manninen V: Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki heart study frame population. Ann Intern Med 24: 41-45, 1993
36. Group of Physicians of the Newcastle upon Tyne Region: Trial of clofibrate in the treatment of ischaemic heart disease. Five year study. Br Med J 4:767-775, 1971
37. Oliver MF, Boyd GS: Influence of reduction of serum lipids on prognosis of coronary heart-disease. A five year study using estrogen. Lancet 2:499-505, 1961
38. Schock HK: The US veterans administration cardiology drug-lipid study: an interim report. Adv Exp Med Biol 4:405-420, 1968
39. Research Committee of the Scottish Society of Physicians: Ischaemic heart disease: a secondary prevention trial using clofibrate. Br Med J 4:775-784, 1971
40. Dewar HA, Oliver MF: Trial of clofibrate. Br Med J 1:506, 1972
41. Carlson LA, Rosenhamer G: Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 223:405-418, 1988
42. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, et al: Effect of partial bypass surgery on patients with hypercholesterolemia. N Engl J Med 323: 946-955, 1990
43. Furberg CD, Harold PA, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA, Young B: Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 90:1679-1687, 1994
44. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L: Beneficial effects of combined cholestipol-niacine therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257:3233-3240, 1987
45. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apoliprotein B. N Engl J Med 323:1289-1298, 1990
46. Gross L, Figueredo R: Long-term cholesterol-lowering effect of cholestipol resin in humans. J Am Geriatr Soc 21:552-556, 1973
47. McCaughan D: The long-term effects of probucol on serum lipid levels. Arch Intern Med 141:1428-1432, 1981
48. Brensike JF, Levy RI, Kelsey SF, Passamani ER, Richardson JM, Loh IK, et al: Effects of therapy with cholesteryramine on progression of coronary atherosclerosis: results of NHLBI type II coronary intervention study. Circulation 69:313-324, 1984
49. Walldius G, Erikson U, Olsson AG, Bergstrand L, Haadell K, Johansson J, Kaijser L, Lassvik C, Moellgaard J, Holme I: The effect of probucol on femoral atherosclerosis. The Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 74:875-883, 1994
50. Sahni RS, Maniet AR, Voci C, Banka VS: Prevention of restenosis by lovastatin after successful coronary angioplasty. Am Heart J 121:1600-1608, 1991
51. Watts GF, Lewis B, Brunt JNH, Lewis ES, Coltart DJ, Smith LDR, et al: Effects of coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas atherosclerosis regression study (STARS). Lancet 339:563-569, 1992